Evidence map›Paper›PMID 28702291›Full record

ArticlePneumonia (Nathan Qld.)2016

A longitudinal study of natural antibody development to pneumococcal surface protein A families 1 and 2 in Papua New Guinean Highland children: a cohort study.

Jacinta P Francis, Peter C Richmond, Audrey Michael, Peter M Siba, Peter Jacoby, Belinda J Hales, Wayne R Thomas, Deborah Lehmann, William S Pomat, Anita H J van den Biggelaar

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pneumonia (Nathan Qld.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00219401 (Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00219401 phase2completednot on this map

Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea

TypeinterventionalSponsorPapua New Guinea Institute of Medical ResearchRan2005 to 2010Enrolled318ConditionsPneumonia, Meningitis, Otitis MediaArmsPneumococcal 7 valent conjugate vaccine (Prevenar®)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Differences in Pneumococcal andFrontiers in immunology · 2021
    Trial
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jacinta P FrancisPapua New Guinea Institute of Medical Research, Goroka, EHP Papua New Guinea.
Peter C RichmondSchool of Paediatrics and Child Health, The University of Western Australia, Perth, WA Australia.
Audrey MichaelPapua New Guinea Institute of Medical Research, Goroka, EHP Papua New Guinea.
Peter M SibaPapua New Guinea Institute of Medical Research, Goroka, EHP Papua New Guinea.
Peter JacobyCentre for Biostatistics, Telethon Kids Institute, The University of Western Australia, Perth, WA Australia.
Belinda J HalesDivision of Molecular Biotechnology, Telethon Kids Institute, The University of Western Australia, Perth, WA Australia.
Wayne R ThomasDivision of Molecular Biotechnology, Telethon Kids Institute, The University of Western Australia, Perth, WA Australia.
Deborah LehmannWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Perth, WA Australia.
William S PomatPapua New Guinea Institute of Medical Research, Goroka, EHP Papua New Guinea.
Anita H J van den BiggelaarWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Perth, WA Australia.
Papua New Guinea Institute of Medical Research · PGThe Kids Research Institute Australia · AUUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPneumococcal surface protein A (PspA), a conserved virulence factor essential for

methodsThis cohort study was conducted in the Asaro Valley in the Eastern Highlands Province of Papua New Guinea, of which Goroka town is the provincial capital. The children included in the analysis were participants in a neonatal pneumococcal conjugate vaccine trial (ClinicalTrials.gov NCT00219401) that was conducted between 2005 and 2009. We investigated the development of anti-PspA antibodies in the first 18 months of life relative to URT pneumococcal carriage in Papua New Guinean infants who experience one of the earliest and highest colonisation rates in the world. Blood samples and nasopharyngeal swabs were collected from a cohort of 88 children at ages 3, 9, and 18 months to quantify immunoglobulin G (IgG) levels to PspA families 1 and 2 using an enzyme-linked immunosorbent assay and to determine URT carriage.

resultsSeventy-three per cent (64/88) of infants carried

conclusionOur findings confirm that PspA is immunogenic and indicate that natural anti-PspA immune responses are acquired through exposure and develop with age. PspA may be a useful candidate in an infant pneumococcal vaccine to prevent early URT colonisation.

Indexed as

ChildrenNatural immunityPapua New GuineaPspAStreptococcus pneumoniaeVaccine

Identifiers

PMID28702291
PMCPMC5471893
OpenAlexW2517460885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.